Cat. #157981
DLKP-pHA MDR 1/A cell line
Cat. #: 157981
Sub-type: Continuous
Unit size: 1x10^6 cells / vial
Availability: 3-4 weeks
Organism: Human
Tissue: Lymph Node
Disease: Cancer
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Martin Clynes
Institute: Dublin City University
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: DLKP-pHA MDR 1/A cell line
- Cancer: Lung cancer
- Cancers detailed: Lung carcinoma
- Research fields: Cancer;Cell biology;Drug development
- Tool sub type: Continuous
- Parental cell: DLKP
- Organism: Human
- Tissue: Lymph Node
- Disease: Cancer
- Growth properties: monolayer, slow-growing
- Conditional description: fold resistance comp. toÄÂ? DLKP parent: 15-fold Adriamycin; 12.2 Vincristin; 13.6 VP-16 (Etoposide).
- Description: heterogeneous lung carcinoma population. Epithelial model
- Production details: DLKPÄÂ? transfected with a pHaMDR1/A plasmid (full cDNA for human MDR1 gene) and treated with 50mg/ml adriamycin
- Biosafety level: 1
- Recommended controls: DLKP parental line
Handling
- Format: Frozen
- Growth medium: DMEM/Ham's F12, 5% FCS supplement with 50ng/ml adriamycin at least once/week. Passage 2-3 time weekly, spin after trypsinisation. Freezing: 5% DMSO, freeze at 2x10(6) cells/ml, spin down after reviving
- Unit size: 1x10^6 cells / vial
- Shipping conditions: Dry ice
- Storage conditions: Liquid Nitrogen
- Mycoplasma free: Yes
